Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocortisone acetate + polymyxin b sulfate + neomycin is a long-established **topical anti-inflammatory and antibacterial combination drug** composed of the corticosteroid hydrocortisone acetate and the antibiotics neomycin and polymyxin B sulfate. The product is marketed under brands such as Cortisporin and Otosporin and has been used for corticosteroid-responsive dermatoses with secondary bacterial infection, otitis externa, and certain ophthalmic inflammatory conditions with susceptible bacterial involvement, depending on formulation. Hydrocortisone acetate acts as a **glucocorticoid receptor agonist** to suppress local inflammation, pruritus, and erythema, while neomycin inhibits bacterial protein synthesis through binding to the **30S ribosomal subunit** and polymyxin B disrupts the **bacterial outer and cytoplasmic membranes** by interacting with lipopolysaccharide and membrane phospholipids. It is an approved prescription pharmaceutical and a **small molecule combination** product available from multiple manufacturers, including branded and generic versions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone acetate + polymyxin b sulfate + neomycin.